At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 70 enrolled
Drug / intervention
Buprenorphine transdermal patchdrug
Likely dose
Buprenorphine transdermal patch 10 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Open-Label Study to Examine Plasma Concentrations of Buprenorphine Following Reapplication of 10-mg Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Buprenorphine transdermal patch for Healthy. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the pharmacokinetics of BTDS following same-site patch reapplication after rest intervals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2000
Primary CompletionMar 2001
First PostedDec 2010
TodayJul 2026
First PostedDec 13, 2010
Enrollment StartNov 1, 2000
Primary CompletionMar 1, 2001
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.6 years ago
Interventions
Buprenorphine transdermal patchdrug
Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.